APA (7th ed.) Citation

Q, H., XB, G., YR, C., XX, G., J, Z., W, Z., . . . MZ, W. (2026). The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: A retrospective cohort study. Journal of thoracic disease, 18(1), 23. https://doi.org/10.21037/jtd-2025-1409

Chicago Style (17th ed.) Citation

Q, He, Guo XB, Chen YR, Gao XX, Zhao J, Zhong W, Chen MJ, Xu Y, and Wang MZ. "The Efficacy and Predictive Factors of First-line Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer with Driver or Non-driver Gene Alterations: A Retrospective Cohort Study." Journal of Thoracic Disease 18, no. 1 (2026): 23. https://doi.org/10.21037/jtd-2025-1409.

MLA (9th ed.) Citation

Q, He, et al. "The Efficacy and Predictive Factors of First-line Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer with Driver or Non-driver Gene Alterations: A Retrospective Cohort Study." Journal of Thoracic Disease, vol. 18, no. 1, 2026, p. 23, https://doi.org/10.21037/jtd-2025-1409.